Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ARMP 
Armata Pharmaceuticals Inc (ARMP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: ARMP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.99% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 192.91M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta 1.3 | 52 Weeks Range 0.90 - 7.44 | Updated Date 12/2/2025 |
52 Weeks Range 0.90 - 7.44 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.66 |
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.5 | Actual -0.74 |
Profitability
Profit Margin - | Operating Margin (TTM) -670.92% |
Management Effectiveness
Return on Assets (TTM) -22.2% | Return on Equity (TTM) -3439.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 356246665 | Price to Sales(TTM) 38.17 |
Enterprise Value 356246665 | Price to Sales(TTM) 38.17 | ||
Enterprise Value to Revenue 148.14 | Enterprise Value to EBITDA 15.72 | Shares Outstanding 36329842 | Shares Floating 10974519 |
Shares Outstanding 36329842 | Shares Floating 10974519 | ||
Percent Insiders 69.29 | Percent Institutions 2.09 |
Upturn AI SWOT
Armata Pharmaceuticals Inc
Company Overview
History and Background
Armata Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing phage-based therapeutics for antibiotic-resistant bacterial infections. Founded in 2003 and has evolved from focusing on phage discovery to developing clinical-stage therapeutic candidates.
Core Business Areas
- Phage Therapeutics Development: Development of bacteriophage-based therapies targeting antibiotic-resistant bacteria.
- Clinical Trials: Conducting clinical trials to assess the safety and efficacy of its phage therapy candidates.
- Research and Discovery: Ongoing research and discovery efforts to identify and characterize new phages with therapeutic potential.
Leadership and Structure
SVP Research and Chief Scientific Officer: Mina Pastagia, Ph.D. Armata operates with a typical structure for a biotech company, comprising research, development, clinical, and administrative departments.
Top Products and Market Share
Key Offerings
- AP-PA02: A phage therapy targeting Pseudomonas aeruginosa infections. Currently in Phase 1b/2a clinical trial. Market share is yet to be determined as the product is not yet approved. Competitors include conventional antibiotics and novel antibacterial therapies.
- AP-SA02: A phage therapy targeting Staphylococcus aureus infections. Currently in Phase 1/2 clinical trial. Market share is yet to be determined as the product is not yet approved. Competitors include conventional antibiotics and novel antibacterial therapies.
Market Dynamics
Industry Overview
The industry is focused on addressing the growing threat of antibiotic-resistant infections. There's increasing demand for alternative therapies like phage therapy.
Positioning
Armata is positioned as a pioneer in phage therapy, focusing on difficult-to-treat bacterial infections. Competitive advantages include a proprietary phage library and clinical-stage assets.
Total Addressable Market (TAM)
The TAM for antibacterial therapies is estimated to be in the billions of dollars, with a significant portion representing the market for addressing antibiotic-resistant infections. Armata's positioning targets a niche within this TAM, focusing on specific bacterial infections.
Upturn SWOT Analysis
Strengths
- Proprietary phage library
- Clinical-stage assets
- Expertise in phage therapy
- Targeting unmet medical needs
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Regulatory hurdles for phage therapy approval
- Early stage company
Opportunities
- Partnerships with pharmaceutical companies
- Expanding phage therapy applications
- Government funding for antibiotic resistance research
- Accelerated regulatory pathways
Threats
- Clinical trial failures
- Competition from other antibacterial therapies
- Regulatory delays
- Resistance to phage therapy
Competitors and Market Share
Key Competitors
- XOMA (XOMA)
- Adaptive Phage Therapeutics (Private)
- Felix Biotechnology (Private)
Competitive Landscape
Armata competes with companies developing novel antibacterial therapies, including other phage therapy developers. Its advantages depend on the efficacy and safety of its clinical-stage assets.
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on clinical trial progress and partnerships.
Future Projections: Future growth is projected based on clinical data and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing clinical trials for AP-PA02 and AP-SA02 and securing funding.
Summary
Armata Pharmaceuticals is a biotechnology company focused on phage therapy for antibiotic-resistant infections. Their success hinges on clinical trial outcomes and regulatory approvals. The company has proprietary technologies but faces financial constraints. Successful clinical trials and strategic partnerships are critical for future growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings, press releases, and publicly available information.
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information is based on publicly available data, which may be subject to change. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Armata Pharmaceuticals Inc
Exchange NYSE MKT | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2011-03-09 | CEO & Director Dr. Deborah L. Birx M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://www.armatapharma.com |
Full time employees 60 | Website https://www.armatapharma.com | ||
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.